Cargando…
GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery
Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567792/ https://www.ncbi.nlm.nih.gov/pubmed/33067466 http://dx.doi.org/10.1038/s41467-020-19138-5 |
_version_ | 1783596396763414528 |
---|---|
author | Xu, Min Wang, Wenliang Waglechner, Nicholas Culp, Elizabeth J. Guitor, Allison K. Wright, Gerard D. |
author_facet | Xu, Min Wang, Wenliang Waglechner, Nicholas Culp, Elizabeth J. Guitor, Allison K. Wright, Gerard D. |
author_sort | Xu, Min |
collection | PubMed |
description | Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expansion of GPA chemical diversity using synthetic or medicinal chemistry remains challenging. Here we describe a synthetic biology platform, GPAHex (GPA Heterologous expression), which exploits the genes required for the specialized GPA building blocks, regulation, antibiotic transport, and resistance for the heterologous production of GPAs. Application of the GPAHex platform results in: (1) a 19-fold increase of corbomycin titer compared to the parental strain, (2) the discovery of a teicoplanin-class GPA from an Amycolatopsis isolate, and (3) the overproduction and characterization of a cryptic nonapeptide GPA. GPAHex provides a platform for GPA production and mining of uncharacterized GPAs and provides a blueprint for chassis design for other natural product classes. |
format | Online Article Text |
id | pubmed-7567792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75677922020-10-19 GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery Xu, Min Wang, Wenliang Waglechner, Nicholas Culp, Elizabeth J. Guitor, Allison K. Wright, Gerard D. Nat Commun Article Glycopeptide antibiotics (GPAs) are essential for the treatment of severe infectious diseases caused by Gram-positive bacteria. The emergence and spread of GPA resistance have propelled the search for more effective GPAs. Given their structural complexity, genetic intractability, and low titer, expansion of GPA chemical diversity using synthetic or medicinal chemistry remains challenging. Here we describe a synthetic biology platform, GPAHex (GPA Heterologous expression), which exploits the genes required for the specialized GPA building blocks, regulation, antibiotic transport, and resistance for the heterologous production of GPAs. Application of the GPAHex platform results in: (1) a 19-fold increase of corbomycin titer compared to the parental strain, (2) the discovery of a teicoplanin-class GPA from an Amycolatopsis isolate, and (3) the overproduction and characterization of a cryptic nonapeptide GPA. GPAHex provides a platform for GPA production and mining of uncharacterized GPAs and provides a blueprint for chassis design for other natural product classes. Nature Publishing Group UK 2020-10-16 /pmc/articles/PMC7567792/ /pubmed/33067466 http://dx.doi.org/10.1038/s41467-020-19138-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Xu, Min Wang, Wenliang Waglechner, Nicholas Culp, Elizabeth J. Guitor, Allison K. Wright, Gerard D. GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title | GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title_full | GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title_fullStr | GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title_full_unstemmed | GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title_short | GPAHex-A synthetic biology platform for Type IV–V glycopeptide antibiotic production and discovery |
title_sort | gpahex-a synthetic biology platform for type iv–v glycopeptide antibiotic production and discovery |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567792/ https://www.ncbi.nlm.nih.gov/pubmed/33067466 http://dx.doi.org/10.1038/s41467-020-19138-5 |
work_keys_str_mv | AT xumin gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery AT wangwenliang gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery AT waglechnernicholas gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery AT culpelizabethj gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery AT guitorallisonk gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery AT wrightgerardd gpahexasyntheticbiologyplatformfortypeivvglycopeptideantibioticproductionanddiscovery |